NASDAQ
14.40USD
+0.11 (+0.77%)
We have scored 5 news catalysts on Delcath Systems, Inc. (DCTH) over the past 12 months. The biggest single-day move next to one of them came Dec 3, 2025, when DCTH closed +3.8%: “Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma”. Coverage across the window leans positive (average ticker sentiment +0.60). Most of the impact sits in revenue growth rate and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
499.7M
P/E
—
EPS
—
Beta
0.60
52W range
8.12-17.42
Day range
14.22–14.55
Open
14.55
Prev close
14.29
Volume
386.8K
Avg volume
448.4K
Dividend
0.00
IPO
2018-05-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Delcath Systems, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DCTH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
